The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid

Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC). The ATP-binding cassette (ABC) family of transporters includes P-glycoprote...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Karbownik, Agnieszka, Sobańska, Katarzyna, Płotek, Włodzimierz, Grabowski, Tomasz, Klupczynska, Agnieszka, Plewa, Szymon, Grześkowiak, Edmund, Szałek, Edyta
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2019
Gaiak:
Preclinical Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7211195/
https://ncbi.nlm.nih.gov/pubmed/31177402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00806-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak